Key facts
- This page summarizes Philippe Busque's Form 4 filing for Cytek Biosciences, Inc. (CTKB).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Mar 2025, 17:52.
Philippe Busque - 04 Mar 2025 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)
- Reporting relationship
- SVP, GLOBAL SALES AND SERVICES
- Issuer ticker
- CTKB
- Reported as of
- 04 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2025, 17:52:42 UTC
- Prior SEC filing
- 20 Nov 2024
- Next SEC filing
- 12 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Valerie Barnett, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Philippe Busque filed Form 4 for Cytek Biosciences, Inc. (CTKB) on 06 Mar 2025.
Change
- Previous filing in this sequence was filed on 20 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTKB
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +91,911
- Change %
- Price
- $0.000000
- Shares after
- 91,911
- Date
- 04 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 91,911
- Exercise price
- $4.31
- Footnotes
- F1
CTKB
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +58,004
- Change %
- Price
- $0.000000
- Shares after
- 58,004
- Date
- 04 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 58,004
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 4, 2025 and each month thereafter until fully vested.
Footnote F2
Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested.